CTLA4 and familial pancreatic carcinoma: Ipilimumab, an anti-CTLA-4 IgG1 monoclonal antibody (mAb), is approved for cancer therapy in USA and Europe in 2011. A phase Ib clinical trial showed that gemcitabine and ipilimumab is a safe regimen with tolerable adverse events for pancreatic cancer, with a median progression-free survival (PFS) of 2.78 months (95% CI 1.61–4.83) and median overall survival (OS) of 6.90 months (95% CI 2.63–9.57) (123).